Source: FiercePharma As the FDA gets set to decide whether Sanofi and Regeneron’s atopic dermatitis drug, Dupixent, can make a bid for asthma sales, the companies are churning out data in a variety of other conditions in hopes of boosting the product even more. The latest? Positive numbers from two phase 3 trials…...